Anti-CD22 monoclonal antibody-toxin conjugate - Galileo Research/the University of Texas

Drug Profile

Anti-CD22 monoclonal antibody-toxin conjugate - Galileo Research/the University of Texas

Alternative Names: IMTOX 22 N97A; IMTOX-22; RFB4-N97A

Latest Information Update: 13 Feb 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Royal Free and University College Medical School; University of Texas Southwestern Medical Center
  • Developer Galileo Research; National Cancer Institute (USA)
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported B cell lymphoma

Most Recent Events

  • 13 Feb 2014 No development reported - Phase-I for B-cell lymphoma in USA (Parenteral)
  • 24 Nov 2010 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top